FAM186B

Across TCGA pan-cancer cohorts, FAM186B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM186B data layer compared with 21 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher FAM186B Mutation is associated with better overall survival. In most high-consensus cancer types, elevated FAM186B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, HNSC, and PRAD are the cancer types where FAM186B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	All	1.000	0.863	.011	20	view →
HNSC	DFS	Median	II,III,IV	0.170	0.662	.016	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	All	0.246	0.690	.025	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

FAM186B–UCEC (OS)

Open the UCEC breakdown →